Acceptability of Overdose Prevention Sites in the Business Community in Baltimore, Maryland.
Business support of harm reduction
Harm reduction
Opioid epidemic
Overdose prevention sites
Journal
Journal of urban health : bulletin of the New York Academy of Medicine
ISSN: 1468-2869
Titre abrégé: J Urban Health
Pays: United States
ID NLM: 9809909
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
15
04
2022
pubmed:
25
5
2022
medline:
11
8
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
Intervetions are urgently needed to reduce the trajectory of the US opioid overdose epidemic, yet implementation is often hampered by resistance or opposition from key community stakeholders. While businesses are economically and physically impacted by the opioid epidemic, they are rarely engaged in efforts to reduce its impact. The establishment of overdose prevention sites (OPS) is being discussed throughout many US jurisdictions with limited attention to the potential positive role of businesses in that process. We surveyed business owners and employees of businesses located in neighborhoods with concentrated drug markets. The study's primary aim was to examine their attitudes to locally-placed OPS. An iterative, two-phase sampling strategy was used to identify recruitment zones. In person (December 2019-March 2020) and telephone-based (April-July 2020) surveys were administered to distinct business owners and employees (N = 149). Sixty-five percent of participants supported OPS in their neighborhood and 47% had recently witnessed an overdose in or around their workplace. While 70% had heard of naloxone, and 38% reported having it on the premises. Correlates of supporting an OPS locally included living in the same neighborhood as work (adjusted odds ratio (aOR) 1.99, 95% confidence intervals (CI): 1.30-3.05); having a more positive attitude towards people who use drugs (aOR 1.33, 95% CI: 1.13-1.58); and having recently seen an overdose in/around the workplace (aOR 2.86, 95% CI: 1.11-7.32). Lack of support being an owner (aOR 0.35, 95% CI: 0.15-0.83). These data indicate the extent to which businesses are directly impacted by the opioid epidemic and the power of personal experience in shaping OPS support in advocacy efforts.
Identifiants
pubmed: 35610474
doi: 10.1007/s11524-022-00647-1
pii: 10.1007/s11524-022-00647-1
pmc: PMC9129898
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
723-732Subventions
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007292
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Centers for Disease Control and Prevention. Drug Overdose Deaths in the U.S. Top 100,000 Annually. Secondary Drug Overdose Deaths in the U.S. Top 100,000 Annually 2021. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm .
Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: a rapid phone survey in Baltimore, Maryland. Drug Alcohol Depend. 2021;221:108584. https://doi.org/10.1016/j.drugalcdep.2021.108584 .
doi: 10.1016/j.drugalcdep.2021.108584
pubmed: 33607497
pmcid: 7881742
Centers for Disease Control and Prevention. Drug Overdose Deaths. Secondary Drug Overdose Deaths. 2019. https://www.cdc.gov/drugoverdose/data/statedeaths.html . Accessed 19 2020.
Drug Policy Alliance. The Drug War, Mass Incarceration and Race. 2018. https://drugpolicy.org/resource/drug-war-massincarceration-and-race-englishspanish . Accessed 8 Feb 2022.
Sherman S, Hunter K, Rouhani S. Safe drug consumption spaces: a strategy for Baltimore City; http://www.abell.org/sites/default/files/files/Safe%20Drug%20Consumption%20Spaces%20final.pdf ; Accessed October 10, 2017 2017.
Kennedy-Hendricks A, Bluestein J, Kral, AH, Barry CL, Sherman SG. Establishing Sanctioned Safe Consumption Sites in the United States: Five Jurisdictions Moving the Policy Agenda Forward. Psychiatric Services. 2019;70(4): 294–301.
Tyndall MW, Wood E, Zhang R, Lai C, Montaner JS, Kerr T. HIV seroprevalence among participants at a supervised injection facility in Vancouver, Canada: implications for prevention, care and treatment. Harm Reduct J. 2006;3:36. https://doi.org/10.1186/1477-7517-3-36 .
doi: 10.1186/1477-7517-3-36
pubmed: 17176481
pmcid: 1766348
Wood E, Kerr T, Stoltz J, et al. Prevalence and correlates of hepatitis C infection among users of North America’s first medically supervised safer injection facility. Public Health. 2005;119(12):1111–5. https://doi.org/10.1016/j.puhe.2005.05.006 .
doi: 10.1016/j.puhe.2005.05.006
pubmed: 16214189
Bayoumi AM, Strike CJ. Making the case for supervised injection services. Lancet. 2016;387(10031):1890–1. https://doi.org/10.1016/s0140-6736(16)30308-7 .
doi: 10.1016/s0140-6736(16)30308-7
pubmed: 27203635
Davidson PJ, Lambdin BH, Browne EN, Wenger LD, Kral AH. Impact of an unsanctioned safe consumption site on criminal activity, 2010–2019. Drug Alcohol Depend. 2021;220:108521. https://doi.org/10.1016/j.drugalcdep.2021.108521 .
doi: 10.1016/j.drugalcdep.2021.108521
pubmed: 33485010
Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006;1:13. https://doi.org/10.1186/1747-597x-1-13 .
doi: 10.1186/1747-597x-1-13
pubmed: 16722550
pmcid: 1471778
Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm Reduct J. 2017;14(1):29. https://doi.org/10.1186/s12954-017-0153-2 .
doi: 10.1186/s12954-017-0153-2
pubmed: 28532488
pmcid: 5441005
Irwin A, Jozaghi E, Bluthenthal RN, Kral AH. A cost-benefit analysis of a potential supervised injection facility in San Francisco, California, USA. J Drug Issues. 2016;0(0):1–21. https://doi.org/10.1177/0022042616679829 .
Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37. https://doi.org/10.1016/s0140-6736(10)62353-7 .
doi: 10.1016/s0140-6736(10)62353-7
pubmed: 21497898
Wood E, Kerr T, Small W, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004;171(7):731–4. https://doi.org/10.1503/cmaj.1040774 .
doi: 10.1503/cmaj.1040774
pubmed: 15451834
pmcid: 517857
Strike C, Jairam JA, Kolla G, et al. Increasing public support for supervised injection facilities in Ontario, Canada. Addiction. 2014;109(6):946–53. https://doi.org/10.1111/add.12506 .
doi: 10.1111/add.12506
pubmed: 24520984
Rouhani S, White RH, Park JN, Sherman SG. High willingness to use overdose prevention sites among female sex workers in Baltimore, Maryland. Drug Alcohol Depend. 2020;212:108042. https://doi.org/10.1016/j.drugalcdep.2020.108042 .
doi: 10.1016/j.drugalcdep.2020.108042
pubmed: 32416474
Park JN, Rouhani S, Morales K, Green TC, McKenzie M, Marshall BDL, Sherman SG. Willingness to use safer consumption spaces among opioid users at high risk of fentanyl overdose in Baltimore, Providence, and Boston. J Urban Health. 2019;96(3):353–366.
Harris RE, Richardson J, Frasso R, Anderson ED. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia. Int J Drug Policy. 2018;52:56–61. https://doi.org/10.1016/j.drugpo.2017.11.005 .
doi: 10.1016/j.drugpo.2017.11.005
pubmed: 29241143
Bouvier BA, Elston B, Hadland SE, Green TC, Marshall BD. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study. Harm Reduct J. 2017;14(1):13.
doi: 10.1186/s12954-017-0139-0
Barry CL, Sherman SG, Stone E, et al. Arguments supporting and opposing legalization of safe consumption sites in the U.S. Int J Drug Policy. 2019;63:18–22. https://doi.org/10.1016/j.drugpo.2018.10.008 .
doi: 10.1016/j.drugpo.2018.10.008
pubmed: 30468971
Kral AH, Davidson PJ. Addressing the nation’s opioid epidemic: lessons from an unsanctioned supervised injection site in the U.S. Am J Prev Med. 2017;53(6):919–22. https://doi.org/10.1016/j.amepre.2017.06.010 .
doi: 10.1016/j.amepre.2017.06.010
pubmed: 28801014
Salmon AM, Thein HH, Kimber J, Kaldor JM, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? Int J Drug Policy. 2007;18(1):46–53. https://doi.org/10.1016/j.drugpo.2006.11.010 .
doi: 10.1016/j.drugpo.2006.11.010
pubmed: 17689343
Barry CL, Sherman SG, McGinty EE. Language matters in combatting the opioid epidemic: Safe consumption sites versus overdose prevention sites. Am J Public Health. 2018;108(9):1157–1159.
Freeman K, Jones CG, Weatherburn DJ, Rutter S, Spooner CJ, Donnelly N. The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug Alcohol Rev. 2005;24(2):173–84. https://doi.org/10.1080/09595230500167460 .
doi: 10.1080/09595230500167460
pubmed: 16076587
Bernstein SE, Bennett D. Zoned out: “NIMBYism”, addiction services and municipal governance in British Columbia. Int J Drug Policy. 2013;24(6):e61–5.
doi: 10.1016/j.drugpo.2013.04.001
Tempalski B. Placing the dynamics of syringe exchange programs in the United States. Health Place. 2007;13(2):417–31.
doi: 10.1016/j.healthplace.2006.05.004
Strike CJ, Myers T, Millson M. Finding a place for needle exchange programs. Crit Public Health. 2004;14(3):261–75.
doi: 10.1080/09581590400004386
Kolla G, Strike C, Watson TM, Jairam J, Fischer B, Bayoumi AM. Risk creating and risk reducing: community perceptions of supervised consumption facilities for illicit drug use. Health Risk Soc. 2017;19(1–2):91–111.
doi: 10.1080/13698575.2017.1291918
Maher L, Salmon A. Supervised injecting facilities: how much evidence is enough? Drug Alcohol Rev. 2007;26(4):351–3. https://doi.org/10.1080/09595230701373818 .
doi: 10.1080/09595230701373818
pubmed: 17564869
Sherman SG, Tomko C, White RH, et al. Structural and environmental influences increase the risk of sexually transmitted infection in a sample of female sex workers. Sex Transm Dis. 2021;48(9):648–53. https://doi.org/10.1097/olq.0000000000001400 .
doi: 10.1097/olq.0000000000001400
pubmed: 33633073
pmcid: 8360669
Allen ST, Footer KHA, Galai N, Park JN, Silberzahn B, Sherman SG. Implementing targeted sampling: lessons learned from recruiting female sex workers in Baltimore, MD. J Urban Health. 2019;96(3):442–51. https://doi.org/10.1007/s11524-018-0292-0 .
doi: 10.1007/s11524-018-0292-0
pubmed: 30066174
Roth AM, Kral AH, Mitchell A, Mukherjee R, Davidson P, Lankenau SE. Overdose prevention site acceptability among residents and businesses surrounding a proposed site in Philadelphia, USA. J Urban Health. 2019;96(3):341–52.
doi: 10.1007/s11524-019-00364-2
Schneider KE, Nestadt DF, White RH, Silberzahn BE, Sherman SG. Conceptualizing overdose trauma: the relationships between experiencing and witnessing overdoses with PTSD Symptoms among female sex workers in Baltimore, Maryland. Int J Drug Policy. 2020;92:102859.
Fadlallah R, El-Jardali F, Nomier M, et al. Using narratives to impact health policy-making: a systematic review. Health Res Policy Syst. 2019;17(1):26.
Epstein D, Farina C, Heidt J. The value of words: narrative as evidence in policy making. Evid Policy. 2014;10(2):243–58.
Milloy MJ, Wood E. Emerging role of supervised injecting facilities in human immunodeficiency virus prevention. Addiction. 2009;104(4):620–1. https://doi.org/10.1111/j.1360-0443.2009.02541.x .
doi: 10.1111/j.1360-0443.2009.02541.x
pubmed: 19335659
Salmon AM, Thein H-H, Kimber J, Kaldor JM, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? Int J Drug Policy. 2007;18(1):46–53.
doi: 10.1016/j.drugpo.2006.11.010
Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med.2019;16(11). ARTN e1002969. https://doi.org/10.1371/journal.pmed.1002969